GlassScriptPhysician profile
Anthony Chindeu Amagwu
NPI 1710159058
$3,932.74
in general payments reported to CMS, 2019-2025
43 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $1,022 · 2023: $1,028 · 2024: $933 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.65 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $499.39 | 2021-2024 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $353.95 | 2021-2025 | |
| Teleflex LLC | $330.08 | 2021-2024 | Urolift |
| Astellas Pharma US INC | $330.06 | 2021-2025 | Xtandi, Myrbetriq |
| Rochester Medical Corporation | $276.22 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $245.07 | 2023-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $209.33 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Alnylam Pharmaceuticals INC. | $146.97 | 2022 | |
| Urogen Pharma, INC. | $145.20 | 2022-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $140.78 | 2022-2025 | Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $107.90 | 2022-2024 | Provenge |
| Boston Scientific Corporation | $94.13 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $81.82 | 2023-2024 | Ultomiris |
| Tolmar Pharmaceuticals, INC. | $81.65 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $63.47 | 2024-2025 | Bard Urinary Drainage Bag, Magic3 Go Intermittent Urinary Catheter |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $59.21 | 2023-2024 | |
| Laborie Medical Technologies Corp. | $55.35 | 2025 | Endosheath Technology |
| Ferring Pharmaceuticals INC. | $47.55 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $46.00 | 2022-2025 | |
| Accord Healthcare, INC. | $45.27 | 2023-2025 | |
| Edap Technomed INC | $45.00 | 2024 | |
| Progenics Pharmaceuticals, INC. | $43.43 | 2022-2024 | |
| Photocure INC | $39.34 | 2022-2025 | Cysview |
| Abbvie INC. | $39.00 | 2022-2024 | |
| Genzyme Corporation | $33.58 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $31.06 | 2021-2022 | |
| Myovant Sciences INC. | $30.59 | 2021-2022 | |
| Blue Earth Diagnostics | $29.18 | 2022 | |
| Caris Mpi, INC. | $29.12 | 2025 | Mi Cancer Seek |
| Urovant Sciences INC | $25.92 | 2022 | |
| Tempus Ai, INC | $25.18 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.33 | 2024 | |
| Axonics, INC. | $23.13 | 2023 | Axonics |
| Foundation Medicine, INC. | $20.11 | 2023 | |
| Endo USA, INC. | $17.23 | 2025 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $16.31 | 2021 | |
| Koelis INC. | $15.92 | 2023 | |
| Immunitybio, INC. | $15.33 | 2024 | |
| Eisai INC. | $15.30 | 2021 | |
| Olympus America INC. | $15.26 | 2023 | Oes Cystonephrofiberscope |
| Amgen INC. | $15.05 | 2024 | Prolia |
| Sagent Pharmaceuticals | $13.23 | 2023 | Glydo |
| Clarus Therapeutics INC. | $10.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Amagwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.